Found 110 matching trials
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
PHASE1This Phase I/IIa clinical study is testing an experimental treatment called...
Location
Hospital Clínic de Barcelona
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
PHASE2This trial aims to demonstrate the feasibility of this approach to reliably...
Location
AHN Cancer Institute - West Penn Hospital
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
PHASE1This study is a single-center, open-label, dose-exploration study to observ...
Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
PHASE1SJCAR19 is a research study seeking to evaluate the use of chimeric antigen...
Status
Active Not Recruiting
Location
St. Jude Children's Research Hospital
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
PHASE1Multi-center, open-label, first in human Phase 1 study of the safety, toler...
Location
Mayo Clinic of Arizona
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
PHASE1This is a first in human dose escalation trial to determine the safety of a...
Status
Active Not Recruiting
Location
Children's Hospital of Philadelphia
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
PHASE1Intravenous infusion of CART cells in the treatment of solid tumors may be ...
Location
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
PHASE1Phase I/II study of adoptive immunotherapy for advanced MUC1\* positive bre...
Location
City of Hope Medical Center
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
PHASE1Evaluation of the efficacy and safety of CD22-targeted chimeric antigen rec...
Location
PersonGen·Anke cellular therapeutics Co., Ltd
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
PHASE1This is an investigator-initiated, multicenter, open-label study of C-CAR16...
Location
Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University